A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells

IM Sroka, EH Heiss, L Havlicek, F Totzke, Y Aristei… - Molecular …, 2010 - ASPET
Abnormal vascular smooth muscle cell (VSMC) proliferation contributes to the pathogenesis
of restenosis. Thus, drugs interfering with cell cycle progression in VSMC are promising …

[HTML][HTML] Roscovitine in cancer and other diseases

J Cicenas, K Kalyan, A Sorokinas… - Annals of …, 2015 - ncbi.nlm.nih.gov
Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …

A newly synthesized Ligustrazine stilbene derivative inhibits PDGF-BB induced vascular smooth muscle cell phenotypic switch and proliferation via delaying cell cycle …

C Peng, S Zhang, H Liu, Y Jiao, G Su, Y Zhu - European Journal of …, 2017 - Elsevier
Abstract Vascular Smooth muscle cells (VSMCs) possess remarkable phenotype plasticity
that allows it to rapidly adapt to fluctuating environmental cues, including the period of …

[HTML][HTML] The role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclin-dependent kinase (Cdk) inhibitor-roscovitine

M Hassan, H Sallam, Z Hassan - Sultan Qaboos University Medical …, 2011 - ncbi.nlm.nih.gov
Pharmacokinetics, pharmacodynamics and pharmacogenetics play an important role in drug
discovery and contribute to treatment success. This is an essential issue in cancer treatment …

[HTML][HTML] Roscovitine inhibits ERK1/2 activation induced by angiotensin II in vascular smooth muscle cells

AY Li, M Han, B Zheng, JK Wen - FEBS letters, 2008 - Elsevier
Roscovitine is a potent CDK inhibitor often used as a biological tool in cell-cycle studies, but
its working mechanism and real targets in vascular smooth muscle cells (VSMCs) remain …

Roscovitine attenuates intimal hyperplasia via inhibiting NF-κB and STAT3 activation induced by TNF-α in vascular smooth muscle cells

M He, C Wang, J Sun, Y Liu, H Wang, J Zhao… - Biochemical …, 2017 - Elsevier
Roscovitine is a selective CDK inhibitor originally designed as anti-cancer agent, which has
also been shown to inhibit proliferation in vascular smooth muscle cells (VSMCs). However …

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

K Bettayeb, N Oumata, A Echalier, Y Ferandin… - Oncogene, 2008 - nature.com
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …

Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study

M Kolodziej, C Goetz, P Di Fazio… - Oncology …, 2015 - spandidos-publications.com
Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Rubiarbonone C inhibits platelet‐derived growth factor‐induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK …

HS Park, KT Quan, JH Han, SH Jung… - British journal of …, 2017 - Wiley Online Library
Background and Purpose The proliferation and migration of vascular smooth muscle cells
(VSMCs) induced by platelet‐derived growth factor (PDGF) are important steps in …

Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases

J Liebl, V Krystof, G Vereb, L Takács, M Strnad… - Angiogenesis, 2011 - Springer
Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being
developed as anticancer therapeutics due to their antiproliferative properties. The purine …